Rapid Dose Therapeutics provides proprietary oral and non-invasive drug delivery technologies designed for applications of many different types of health products.
Chemesis International Inc. (OTC: CADMF) (CSE: CSI), and Rapid Dose Therapeutics Inc. (“RDT”), a Canadian bio-technology company, which provides disruptive proprietary drug delivery technologies designed to improve patient outcomes, are proud to announce they have signed an additional definitive agreement to bring QuickStrip™ Oral Thin Strips to Puerto Rico. The Company previously announced on October 12, 2018 a definitive agreement to produce QuickStrips™ for the state of California.
Under the terms of the agreement, Chemesis will receive rights to produce, distribute and sell QuickStrip products, with exclusive rights for the cannabis market in Puerto Rico. This partnership allows Chemesis to further strengthen its position in Puerto Rico by allowing the Company to use a convenient drug delivery system that can target a variety of consumers and also allow them to use cannabis products in a new way. The Company will continue to position itself to capitalize in this growing market with innovative and effective products.
“We are pleased to bring RDT and their QuickStrip™ Oral Thin Strips to another growing cannabis market, and we believe this will allow the Company to further increase its market position in Puerto Rico,” said CEO of Chemesis, Edgar Montero. “With RDT recently announcing Aphria as a partner in select global markets, we feel our partnership will add tremendous value to our shareholders.”
“RDT is excited to continue to partner with Chemesis to offer cannabis consumers in Puerto Rico a smoke-free delivery method that is consistent and precise,” explains Mark Upsdell, CEO of RDT. “With Chemesis’ worldwide reach and exclusive partnerships, the QuickStrip™ brand will have the opportunity to establish and grow new markets around the globe.”